Cytotoxicity against Human Tumor Cells Mediated by the Conjugate of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody to Recombinant Ricin A Chain

Cancer Research

Volumn 49, Issue 13, 1989, Pages 3482-3488

  Masui, Hideo ^a   Kamrath, Heidi ^a   Mendelsohn, John ^a   Apell, Gerald ^b,c   Houston, L L ^b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Celas Corporation ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RICIN A;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CELL CULTURE; DRUG CONJUGATE; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; HUMAN; IMMUNOTHERAPY; IMMUNOTOXINS; IN VITRO; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RICIN; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0024361386     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Frankel, A. E. Antibody-toxin hybrids: a clinical review of their use. J. Biol. Response Modif., 4: 437–469, 1985.
2. Houghton, A. N., and Scheinberg, D. A. Monoclonal antibodies: potential applications to the treatment of cancer. Semin. Oncol., 13: 165–179,1986.
3. Vitetta, E. S., Fulton, R. J., May, R. D., Till, M., and Uhr, J. W. Redesigning nature’ poisons to create anti-tumor reagents. Science (Wash. DC), 238: 1098–1104(1987).
4. Steplewski, Z., Herlyn, D., Maul, G., and Kaprowski, H. Hypothesis: macrophages as effector cells for human tumor destruction mediated by monoclonal antibody. Hybridoma, 2: 1–5,1983.
5. Masui, H., Morayama, T., and Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res., 46: 5592-5598,1986.
6. Denkers, E. Y., Badger, C. C., Ledbetter, J. A., and Bernstein, I. D. Influence of antibody isotype on passive immunotherapy of lymphoma. J. Immunol., 755: 2183–2185,1985.
7. Jensen, F. K., Blythman, H. E., Carriere, D., Casellas, P., Gros, O., Gros, P., Laurent, J. C., Paolucci, F., Pau, B., Poncelet, P., Richter, G., Vidal, H., and Voisin, G. A. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol. Rev., 62: 185–216,1982.
8. Vitetta, E. S., Krolick, K. A., Miyama-Inaba, M., Cushley, W., and Uhr, W. Immunotoxins: a new approach to cancer therapy. Science (Wash. DC), 219: 644–650,1983.
9. Baldwin, R. W. Immunotherapy of cancer. Cancer Chemotherapy. Ann., 6: 181–199,1984.
10. Pastan, I., and Willingham, M. C. Immunotoxins. Cell, 47: 641–648,1986.
11. Olsnes, S., Defsnes, K., and Pihl, A. Mechanism of action of the toxic lectins abrin and ricin. Nature (Lond.), 249: 627–731,1974.
12. Olsnes, S., Sandrig, K., Defsnes, K., and Pihl, A. Rates of different steps involved in the inhibition of protein synthesis by the toxic lectins abrin and ricin. J. Biol. Chem., 251: 3985–3992,1976.
13. Endo, Y., Mitsui, K., Motiyuki, M., and Tsurugi, K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J. Biol. Chem., 262: 5908–5912,1987.
14. Schlom, J. Basic principles and applications of monoclonal antibodies in the management of carcinomas. Cancer Res., 46: 3225–3238,1986.
15. Sunada, H., Magun, B., Mendelsohn, J., and MacLeod, C. L. Monoclonal antibody against EGF receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sei. USA, 83: 3825–3829,1986.
16. Kamata, N., Chida, K., Rikimaru, K., Horikoshi, M., Enomoto, S., and Kuroki, T. Growth-inhibitory effects of epidermal growth factor and over-expression of its receptors on human squamous cell carcinomas in culture. Cancer Res., 46: 1648–1653,1986.
17. Hendler, F., Shum, A., Richards, C., Cassels, D., Guasterson, B., and Ozanne, B. Evidence for increased epidermal growth factor receptors in epidermal malignancies. Cancer Cells, 1: 41–50,1984.
18. Liberman, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., and Schlesinger, J. Amplification enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature (Lond.), 313: 144–147,1985.
19. Filmus, J., Pollak, M. N., Cailleau, R., and Buick, R. N. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun., 128: 898–905,1985.
20. Fitzpatrick, S., LaChance, M. P., and Schultz, G. S. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res., 44: 3442–3447,1984.
21. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. Synthesis of messenger RNAs for transforming growth factor and the epidermal growth factor receptor by human tumors. Cancer Res., 47: 707–712,1987.
22. Sato, J. D., Kawamoto, T., Le, A., Mendelsohn, J., Polikoff, J., and Sato, G. H. Biological effects in vitro of monoclonal antibodies to human EGF receptors. Mol. Biol. Med., 1: 511–529,1983.
23. Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., and Mendelsohn, J. Growth stimulation of A431 cells by epidermal growth factor identification of high-affinity receptors for epidermal growth factor by anti-receptor monoclonal antibody. Proc. Natl. Acad. Sei. USA, 80: 1337–1341,1983.
24. Kawamoto, T., Mendelsohn, J., Le, A., Sato, G. H., Lazar, C. S., and Gill, G. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem., 259: 7761–7766, 1984.
25. Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., MacLeod, C. L., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755–7760,1984.
26. Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., and Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 44: 1002–1007, 1984.
27. Mendelsohn, J., Masui, H., Sunada, H., and MacLeod, C. L. Monoclonal antibodies against the receptor for epidermal growth factor as potential anticancer agents. In: J. Minna and W. M. Kuehl (eds.), Cellular and Molecular Biology of Tumors and Potential Clinical Applications, pp. 307–312. New York: Alan R. Liss, Inc., 1988.
28. Barnes, D. W. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J. Cell. Biol., 93: 1–4,1982.
29. Gill, G. N., and Lazar, C. S. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature (Lond.), 293: 305–308,1981.
30. MacLeod, C. L., Luk, A., Castagnola, J. M., Cronin, M., and Mendelsohn, J. EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells. J. Cell. Physiol., 127: 175–182,1986.
31. Castagnola, J., MacLeod, C. L., Sunada, H., Mendelsohn, J., and Taetle, R. Effects of epidermal growth factor upon transferrin receptor phosphorylation and surface expression in malignant epithelial cells. J. Cell. Physiol., 132: 492–500 (1987).
32. Piatak, M., Lane, J. A., Laird, W., Björn, M., Wang, A., and Williams, M. Expression of soluble and fully functional ricin A chain in Escherichia coli is temperature sensitive. J. Biol. Chem., 263: 4837–4843,1988.
33. Griffin, T. W., Richardson, C., Houston, L. L., LePage, D., Bogden, A., and Raso, V. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Cancer Res., 47: 4266–4270, 1987.
34. Gregg, E. O., Bridges, S. H., Youle, R. J., Longo, D. L., Houston, L. L., Glennie, M. J., Stevenson, F. K., and Green, I. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy for the guinea pig L2CB cell leukemia. J. Immunol., 138: 4502–4508,1987.
35. Björn, M. J., and Groetsema, G. Immunotoxins to the murine transferrin receptor intracavitary therapy of mice bearing syngeneic peritoneal tumors. Cancer Res., 47: 6639–6645,1987.
36. Wish, L., Furth, J., and Storey, R. H. Direct determinations of plasma, cell, and organ-blood volumes in normal and hypervolemic mice. Proc. Soc. Exp. Biol. Med., 74: 644–648,1950.
37. Dunne, A. JANA, a new iterative polyexponential curve stripping program. Comput. Meth. Prog, in Biomed., 20: 269–275,1985.
38. Casellas, P., Brown, J. P., Gros, O., Gros, P., Hellström, I., Jansen, F. K., Poncelet, P., Roncucci, R., Vidal, H., and Hellström, K. E. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int. J. Cancer, 30: 437–443,1982.
39. Bourne, B. J. P., Casellas, P., Blythman, H. E., and Jansen, F. K. Study of the plasma clearance of antibody-ricin-A-chain immunotoxins: evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur. J. Biochem., 155: 1–10,1986.
40. Thorpe, P. E., Detre, S. I., Foxwell, B. M. J., Brown, H. N. F., Skilleter, D. N., Wilson, G., Forrester, A., and Stripe, F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydrite mixtures: effect on toxicity and in vivo distribution. Eur. J. Biochem., 147: 197–206,1985.
41. Blakey, D. C., Watson, G. J., Knowles, P. P., and Thorpe, P. E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res., 47: 947–952,1987.
42. Fulton, R. J., Tucker, T. F., Vitetta, E. S., and Uhr, J. W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Res., 48: 2618–2625,1988.
43. Fulton, R. J., Uhr, J. W., and Vitetta, E. S. In vivo therapy of the BCLI tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res., 48: 2626–2631,1988.
44. Thorpe, P. E., Wallace, P. M., Knowles, P. P., Reif, M. G., Brown, A. N. F., Watson, B. J., Blakey, D. C., and Newell, D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res., 48: 6396–6403,1988.
45. Fitzgerald, D. J., Björn, M. J., Ferris, R. J., Winkelhake, J. L., Frankel, A. E., Hamilton, T. C., Ozols, R. F., Willingham, M. C., and Pastan, I. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. Cancer Res., 47: 1407–1410,1987.
46. Hara, H., and Seon, B. K. Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models. Proc. Natl. Acad. Sei. USA, 84: 3390–3394,1987.
47. Leonard, J. E., Johnson, D. E., Schawler, D. L., and Dillman, R. O. Inhibition of human T-cell tumor growth by TlOl-ricin A-chain in an athymic mouse model. Cancer Res., 48: 4862–4867,1988.